CompoAtlas

Circuzen

Food supplement declared in France, declaration No 2021-11-4, decision dated 1 November 2021

Circuzen is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
One Man Think Tank EOOD
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules
Directions for use
Prendre 2 gélules par jour à avaler avec un grand verre d’eau
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking anticoagulants, Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Blood and lymphatic circulation

Declaration 323748, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Vitis vinifera L.FeuillePoudre (de plantes séchées ou broyées)280 mg
Aesculus hippocastanum L.GraineExtrait sec hydroalcoolique250 mg
Vitis vinifera L.GraineExtrait sec alcoolique130 mg
Glycine max. (L.) Merr.GraineAutre extrait sec50 mg

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
Acide L-ascorbiqueVitamine Cpas de limite (données insuffisantes)180 mg

Additives

E464, E470b

Other ingredients

maltodextrine

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Demander l'avis de votre médecin en cas de prise de médicaments et pour les femmes ayant des antécédents personnels ou familiaux de cancer du sein.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Aesculus hippocastanum L.
    Read the warning, when it applies and the studies cited

    Horse Chestnut - Aesculus Hippocastanum

    Route of administration: Oral (Bradley 2006; ESCOP 2003)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Known adverse reactions

    When using this product you may experience headache, dizziness, gastric irritation, or itchiness (Bradley 2006; Mills and Bone 2005; ESCOP 2003).

    Sources cited by Health Canada (3)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (UK): British Herbal Medicine Association; 2006.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 27 February 2026

  • Glycine max. (L.) Merr.
    Read the warning, when it applies and the studies cited

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line